Literature DB >> 27570928

Evidence-Based Pharmacologic Treatment of Pediatric Bipolar Disorder.

Robert L Findling1.   

Abstract

Pharmacotherapy is an important component of treatment for children and adolescents with bipolar disorder. The body of evidence supporting safe and effective treatments in this population is growing. Available data provide information on the risks and benefits of pharmacologic agents used for acute manic, mixed, and depressive episodes as well as for maintenance treatment. Lithium, anticonvulsants, and antipsychotics comprise the armamentarium for treating pediatric bipolar disorder. When selecting treatment, clinicians must consider the efficacy and side effect profile of potential pharmacotherapies, as well as the patient's history, including the presence of comorbidities, in order to develop a treatment plan that will ensure optimal outcomes. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27570928     DOI: 10.4088/JCP.15017su1c.02

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  A customized adherence enhancement program for adolescents and young adults with suboptimal adherence and bipolar disorder: Trial design and methodological report.

Authors:  Molly McVoy; Melissa Delbello; Jennifer Levin; Avani C Modi; Larry F Forthun; Farren Briggs; Deionte Appling; Michaela Broadnax; Carla Conroy; Raechel Cooley; George Eapen; Martha Sajatovic
Journal:  Contemp Clin Trials       Date:  2022-03-09       Impact factor: 2.261

2.  Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses.

Authors:  Caitlin S Yee; Emily R Hawken; Ross J Baldessarini; Gustavo H Vázquez
Journal:  Int J Neuropsychopharmacol       Date:  2019-08-01       Impact factor: 5.176

3.  A brief motivational intervention for enhancing medication adherence for adolescents with bipolar disorder: A pilot randomized trial.

Authors:  Tina R Goldstein; Megan L Krantz; Rachael K Fersch-Podrat; Nina J Hotkowski; John Merranko; Loren Sobel; David Axelson; Boris Birmaher; Antoine Douaihy
Journal:  J Affect Disord       Date:  2020-01-07       Impact factor: 4.839

4.  Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial.

Authors:  Manpreet K Singh; Andrei Pikalov; Cynthia Siu; Michael Tocco; Antony Loebel
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-05-08       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.